This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout AboutWhy PENBRAYA?Risks of Meningococcal DiseaseGaps in Vaccination CoverageDosing & Recommendations Effectiveness & Safety Effectiveness
& Safety
ImmunogenicitySafety Profile
In Your Practice In Your PracticeSimplified VaccinationHow to Transition to PENBRAYAPreparing PENBRAYAResources ResourcesRequest a RepresentativeMaterialsVideos
Prescribing InformationIndicationsPatient Site
PENBRAYA is the FIRST and ONLY pentavalent (5-in-1) MenABCWY vaccine1,2Now you can help protect against the 5 leading meningococcal serogroups (A, B, C, W, and Y) with PENBRAYA, the only MenABCWY vaccine​ to offer the broadest protection with the fewest injections1-4*
Vaccinate your healthy 16-year-old patients with 5-in-1 PENBRAYA1,5
Vaccinate your healthy 16-year-old patients with 5-in-1 PENBRAYA1,5
One less injection is needed for healthy adolescents at age 16 to complete the recommended meningococcal vaccination schedule compared to separate MenACWY and MenB vaccines.1,4

Helpful information about getting started with PENBRAYA

Why PENBRAYA?

PENBRAYA offers the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) in a single vaccine product

Loading
Dosing and Recommendations

Learn about ACIP-recommended dosing for PENBRAYA

Loading
Simplified Vaccination

PENBRAYA can streamline vaccination for your patients and practice 

Loading

References: 1. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023. 2. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed October 12, 2021. Accessed August 2, 2023.https://www.cdc.gov/vaccines/vpd/mening/index.html 3. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134:103571. 4. Recommended child and adolescent immunization schedule for children and adolescents aged 18 years or younger. Centers for Disease Control and Prevention. Published November 16, 2023. Accessed November 22, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 5. Collins J. Summary of EtR and proposed recommendations for Pfizer’s MenABCWY vaccine. Presented at: Advisory Committee on Immunization Practices (ACIP); October 25, 2023. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-10-25-26/04-Meningococcal-Collins-508.pdf

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-PBI-USA-0145
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-MCL-USA-0367
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age 
Important Safety Information
  • Do not administer PENBRAYA or TRUMENBA to individuals with a history of severe allergic reaction (eg, anaphylaxis) to any component of PENBRAYA or TRUMENBA. Appropriate medical treatment used to manage allergic reactions must be available in the event an anaphylactic reaction occurs immediately following administration of PENBRAYA or TRUMENBA
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including PENBRAYA or TRUMENBA. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence may have reduced immune responses to PENBRAYA or TRUMENBA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis groups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENBRAYA
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis group B, even if they develop antibodies following vaccination with TRUMENBA
  • Vaccination with PENBRAYA or TRUMENBA may not protect all vaccine recipients
  • Vaccination with PENBRAYA does not substitute for vaccination with a tetanus toxoid–containing vaccine to prevent tetanus
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENBRAYA to individuals with a history of GBS should take into account the expected benefits and potential risks 
  • For PENBRAYA, the most commonly reported (≥15%) solicited adverse reactions after Dose 1 and Dose 2, respectively, were pain at the injection site (89% and 84%), fatigue (52% and 48%), headache (47% and 40%), muscle pain (26% and 23%), injection site redness (26% and 23%), injection site swelling (25% and 24%), joint pain (20% and 18%), and chills (20% and 16%)
  • For TRUMENBA, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
  • Data are not available on the safety and effectiveness of using TRUMENBA and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • The safety and effectiveness of PENBRAYA or TRUMENBA have not been established in pregnant individuals
     
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for PENBRAYA and full Prescribing Information for TRUMENBA.
Indications
  • PENBRAYA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. PENBRAYA is approved for use in individuals 10 through 25 years of age
  • TRUMENBA is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. TRUMENBA is approved for use in individuals 10 through 25 years of age